Correlation Between Century Therapeutics and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Century Therapeutics and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Century Therapeutics and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Century Therapeutics and Molecular Partners AG, you can compare the effects of market volatilities on Century Therapeutics and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Century Therapeutics with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Century Therapeutics and Molecular Partners.
Diversification Opportunities for Century Therapeutics and Molecular Partners
0.03 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Century and Molecular is 0.03. Overlapping area represents the amount of risk that can be diversified away by holding Century Therapeutics and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Century Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Century Therapeutics are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Century Therapeutics i.e., Century Therapeutics and Molecular Partners go up and down completely randomly.
Pair Corralation between Century Therapeutics and Molecular Partners
Given the investment horizon of 90 days Century Therapeutics is expected to under-perform the Molecular Partners. But the stock apears to be less risky and, when comparing its historical volatility, Century Therapeutics is 1.62 times less risky than Molecular Partners. The stock trades about -0.06 of its potential returns per unit of risk. The Molecular Partners AG is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest 633.00 in Molecular Partners AG on August 28, 2024 and sell it today you would lose (71.00) from holding Molecular Partners AG or give up 11.22% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Century Therapeutics vs. Molecular Partners AG
Performance |
| Timeline |
| Century Therapeutics |
| Molecular Partners |
Century Therapeutics and Molecular Partners Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Century Therapeutics and Molecular Partners
The main advantage of trading using opposite Century Therapeutics and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Century Therapeutics position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.| Century Therapeutics vs. Eliem Therapeutics | Century Therapeutics vs. HCW Biologics | Century Therapeutics vs. Scpharmaceuticals | Century Therapeutics vs. Milestone Pharmaceuticals |
| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Complementary Tools
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |